(Apr. 26) – Italian pharmaceutical group Recordati has announced the acquisition of the AIC, trademarks and other activities of six OTC medicines in Germany from the companies Cilag GmbH International and McNeil GmbH & Co. OHG. The products acquired are JHP-Rödler (mint oil indicated for digestive disorder, headache, cough and cold), Betadorm D (Diphenhydramine HCl indicated for sleep disorders), Rhinopront (pseudoephedrine+triprolidine indicated for rhinitis and head colds), Collomack Topical (salicylic acid solution, an anti- corn preparation), Tirgon (bisacodyl for constipation) and Xitix (vitamin C lozenges to treat vitamin C deficiency). Estimated 2012 sales for the six products are of around EUR 6 million euros. “The acquisition by our German subsidiary of these six well known brands represents an interesting opportunity to strengthen Recordati Pharma’s OTC product portfolio”, declared Giovanni Recordati, Chairman and CEO of the Recordati Group. “The OTC pharmaceutical segment in Germany is worth around EUR 4 billion and represents a share in units of 52% of the overall pharmaceutical market. Together with the existing OTC portfolio, which includes well known brands such as Mirfulan®, Osteoplus®, Dolobene®, Flosa® and Silibene®, the German subsidiary is now able to better exploit the OTC market potential by building a dedicated sales organization”. (Red/Peg)
